Analysis of the Clinical Effect of Teriparatide and Zoledronic Acid in Postmenopausal Osteoporosis

Abstract

This paper mainly analyzes the clinical effect of teriparatide and zoledronic acid treatment in postmenopausal patients with osteoporosis.56 postmenopausal osteoporosis patients admitted to our hospital were divided into two groups according to the lottery method. 28 patients treated with teriparatide were included in the observation group, and patients treated with zoledronic acid were included in the control group. The study was conducted from January 2021 to September 2022, and the efficacy of the two groups was analyzed and compared.result display, There was no difference between lumbar spine 1-4 and femoral neck BMD, PINP, ALP,β-CTX level, VAS score, BMD level of femoral neck and the probability of adverse drug reactions (P> 0.05); Both groups differ significantly between lumbar 1-4 BMD, femoral neck BMD, PINP, ALP, β -CTX levels, and VAS scores before and after treatment, PINP, ALP, β -CTX levels were higher than before treatment, The control group was lower than before the treatment (P <0.05); The 1-4 BMD levels, PINP, ALP, and β -CTX levels in the treatment observation group were higher than those in the control group (P <0.05); VAS scores at 3 months, 6 months and 1 year compared with the control group (P <0.05). Thus, it is known that teriparatide and zoledronic acid have good therapeutic effects on postmenopausal osteoporosis, which can improve the bone density level of patients, adjust the bone turnover index level, and the medication is relatively safe, but teriparatide is more effective in improving lumbar bone density and reducing pain.